Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | TGM1 | P22735 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19972870 | 1.00 | F13A1 (0.32) | F13A1TGM2TGM1CYP1A2POLB | |
| SCHEMBL19972881 | 1.00 | F13A1 (0.32) | F13A1TGM2TGM1CYP1A2POLB | |
| SCHEMBL28714864 | 0.86 | — | — | |
| SCHEMBL21082824 | 0.80 | BTK (0.30) | — | |
| SCHEMBL15318936 | 0.73 | F13A1 (0.31) | F13A1TGM2TGM1 | |
| SCHEMBL15336723 | 0.73 | F13A1 (0.31) | F13A1TGM2TGM1 | |
| SCHEMBL15318935 | 0.73 | F13A1 (0.31) | F13A1TGM2TGM1 | |
| SCHEMBL21638925 | 0.73 | ACACB (0.36) | F13A1TGM2TGM1 | |
| SCHEMBL994973 | 0.72 | NAMPT (0.36) | F13A1TGM2TGM1 | |
| SCHEMBL16558945 | 0.72 | NFKB1 (0.33) | CYP1A2POLBCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512851-B1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2020-10-13 | — | — | US | disclosed |
| EP-3512851-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | Entasis Therapeutics Limited (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| WO-2018053215-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | LCT, MGAM, MRPL21 | F13A1 3512/4885TGM2 1205/4885TGM1 771/4885 |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | LCT, MGAM, MRPL21 | F13A1 3512/4885TGM2 1205/4885TGM1 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.